• Publications
  • Influence
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of
TLDR
This briefer article should be read as an addendum to the previous full account on the management of hyperglycemia, which described the need to individualize both treatment targets and treatment strategies with an emphasis on patient-centered care and shared decision making. Expand
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
TLDR
This statement has been written incorporating the best available evidence and, where solid support does not exist, using the experience and insight of the writing group, incorporating an extensive review by additional experts (acknowledged below). Expand
American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control
TLDR
Recommendations from the ACE and the ADA generally endorsed tight glycemic control in critical care units and for patients in general medical and surgical units, where RCT evidence regarding treatment targets was lacking, glycemic goals similar to those advised for outpatients were advocated. Expand
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of
TLDR
A briefer article on the management of hyperglycemia in patients with type 2 diabetes, with an emphasis on patientcentered care and shared decision making, is read as an addendum to the previous full account. Expand
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
TLDR
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes. Expand
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
TLDR
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. Expand
How Do We Define Cure of Diabetes?
TLDR
A consensus group of experts comprised of experts in pediatric and adult endocrinology, diabetes education, transplantation, metabolism, bariatric/metabolic surgery, and (for another perspective) hematology-oncology met in June 2009 to discuss issues. Expand
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. Expand
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
TLDR
With few exceptions, the available oral antidiabetic agents are equally effective at lowering glucose concentrations and their mechanisms of action are different, however, and as a result they appear to have distinct metabolic effects. Expand
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
TLDR
This statement has been written incorporating the best available evidence and, where solid support does not exist, using the experience and insight of the writing group, incorporating an extensive review by additional experts (acknowledged below). Expand
...
1
2
3
4
5
...